Studies to be presented by Providence researchers at AACR annual meeting

Wednesday, April 23, 2025

The American Association for Cancer Research (AACR) annual meeting is a much-anticipated event that inspires cross-pollination among the most innovative cancer researchers in the United States.

This year the meeting will be held in Chicago and some of our Providence Cancer Institute researchers will be there to present their study findings.

Read on to see study abstracts by our researchers, including one co-authored by R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed), executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute. The study is an FDA registrational trial that could change the standard of care for head and neck cancer in the near future.

Plenary Series

Abstract CT001: Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study

Authors: R. Bryan Bell, et al.

Mini symposium

Hot Topics in Cancer Prevention: Development of Multi-Cancer Early Detection Tests, Assessment of the Immune Environment, Targets for Cancer Prevention, and Cancer Interception Trials

Introduction: Sasha Stanton

Abstract 3764: Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy

Authors: Bernard A. Fox, R. Bryan Bell, et al.

Abstract 3776: Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinib versus osimertinib in EGFR mutant non-small cell lung cancer

Authors: Rachel Sanborn, et al.

Poster Sessions

Abstract 3389: Genetic and clinical landscape of NUTM1 structural variants

Authors: Brian Piening, et al.

Abstract 6707: Direct in vivo CRISPR screen identifies BAP1 and FAT1 as potent tumor suppressors in sarcomagenesis

Authors: Jianguo Huang, Brian Piening, Brady Bernard, Willam L. Redmond, Walter Urba, et al.

Abstract 4716/14: Functional precision medicine: Uncovering high actionability in rare cancers beyond genomics

Authors: Brady Bernard, et al.

Abstract CT039/18: Results of a first-in-human phase 1 trial of anchored IL-12 drug conjugate (ANK-101)

Authors: Brendan Curti, et al.

Abstract CT149/15: A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor, in patients with advanced or metastatic solid tumors

Authors: Rom Leidner, et al.

Abstract 6473/14: Determining the spatial composition of immune infiltrate in HER2+ breast cancerHER2+ breast cancer

Authors: David Page, Sasha Stanton, et al.

Abstract LB397/3: Biomarker-guided dose selection in the iintune-1 study of dazostinag,a STING agonist, alone and in combination with pembrolizumab for patients with metastatic solid tumors

Authors: Rachel Sanborn, et al.

Abstract 855/11: Dynamics of T cell and T cell receptor following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

Authors: Matthew Taylor, et al.

Abstract LB316: Enabling long-read mRNA-seq for oncology biomarker discovery using limited clinical sample inputs

Authors: R. Bryan Bell, et al.

About Providence Cancer Institute of Oregon

Providence Cancer Institute in Oregon is a leading provider of cancer care in Oregon and a global leader in immuno-oncology. Through its research division, the Earle A. Chiles Research Institute, patients have access to state-of-the-art genomic sequencing, adoptive cellular therapies and a robust clinical research portfolio comprising early phase, investigator-initiated, cooperative group and industry-sponsored trials. Our multidisciplinary care teams partner with patients at every step of care, from prevention and diagnosis to personalized treatment plans, support services and cancer survivorship.  